Scinai Immunotherapeutics Files Updated Business Presentation

Ticker: SCNI · Form: 6-K · Filed: 2024-04-16T00:00:00.000Z

Sentiment: neutral

Topics: filing-update, presentation

TL;DR

Scinai dropped a new investor deck, check it for updates.

AI Summary

Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) has filed a Form 6-K on April 16, 2024, to provide an updated business presentation. This filing incorporates an updated presentation as Exhibit 99.1, which contains new business updates.

Why It Matters

Investors and stakeholders can review the latest business developments and strategic updates from Scinai Immunotherapeutics through this newly filed presentation.

Risk Assessment

Risk Level: low — This filing is an informational update and does not contain significant financial or operational changes that would immediately impact risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report that Scinai Immunotherapeutics Ltd. has made available an updated presentation about its business, incorporated as Exhibit 99.1.

What is the filing date of this report?

The filing date of this report is April 16, 2024.

What was Scinai Immunotherapeutics Ltd. formerly known as?

Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.

Where is Scinai Immunotherapeutics Ltd. located?

Scinai Immunotherapeutics Ltd. is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.

Does the registrant file annual reports under Form 20-F or Form 40-F?

The registrant, Scinai Immunotherapeutics Ltd., indicates that it files annual reports under Form 20-F.

From the Filing

0001213900-24-033533.txt : 20240416 0001213900-24-033533.hdr.sgml : 20240416 20240416172706 ACCESSION NUMBER: 0001213900-24-033533 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20240416 FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 24848797 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0203981-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note Scinai Immunotherapeutics Ltd. (the “Company”) has made available an updated presentation about its business, a copy of which is furnished herewith as Exhibit 99.1 and incorporated by reference. The new updates in the presentation are not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. 1 Exhibit Index Exhibit No. Description 99.1 Scinai Immunotherapeutics Presentation dated April 17, 2024. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: April 16, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3 EX-99.1 2 ea020398101ex99-1_scinai.htm SCINAI IMMUNOTHERAPEUTICS PRESENTATION DATED APRIL 17, 2024 Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE Elevating dermatological drug development through advanced inflammatory marker targeting methodology - Focus of IL - 17 in the pathophysiology of psoriasis and unmet medical need – 5th DDDS Europe, April 17, 2024 Michael P. Schön Department of Dermatology , Venereology and Allergology Lower Saxony Institute of Occupational Dermatology University Medical Center Göttingen, Germany https://hautklinik.umg.eu Conflict of interest: AbbVie, Almirall, BMS, Celltrion, Janssen, Lilly, Novartis, UCB Tamar Ben - Yedidia Scinai Immunotherapeutics Ltd. Jerusalem, Israel https://www.scinai.com Presentation supported by Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) CLICK TO EDIT MASTER TITLE STYLE What is Psoriasis? 1 - 4 • Systemic , chronic inflammatory disorder • Affects 2 – 3% of the fair - skinned population • Genetic and immunologic basis , can be triggered • Several comorbid diseases result in considerable impairment of quality of life • 2016: World Health Organization (WHO) publishes Global Report on Psoriasis 4 WHO: World Health

View on Read The Filing